RxDoctor Payments Data

Gregory Green, MD

Family Medicine · Monroe, LANPI 1093737819

Payments from drug & device makers

$7,647in general payments, 2019–2025

Across 457 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$974
  • Novo Nordisk$678
  • Lilly USA, LLC$633
  • Amgen$621
  • AstraZeneca$567
  • Bayer$501
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,60699%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,647 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$211,368
Medicare patients
532
Services billed
3,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban213$168,902
OzempicSemaglutide133$132,013
JardianceEmpagliflozin89$78,826
KerendiaFinerenone64$60,297
MounjaroTirzepatide48$51,555
TrulicityDulaglutide32$41,221
EntrestoSacubitril/Valsartan38$36,811
JanuviaSitagliptin Phosphate22$34,098
FarxigaDapagliflozin Propanediol30$33,639
XareltoRivaroxaban30$27,268
MyrbetriqMirabegron29$23,322
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,273
LinzessLinaclotide33$21,109
Janumet XrSitagliptin Phos/Metformin Hcl21$15,279
Tresiba Flextouch U-100Insulin Degludec31$15,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$248$168,902213 claims
Novo NordiskOzempic$678$132,013133 claims
Lilly USA, LLCMounjaro, Trulicity$633$92,77680 claims
Boehringer IngelheimJardiance, Tradjenta$91$86,141100 claims
BayerKerendia$501$60,29764 claims
MerckJanuvia, Janumet Xr$213$49,37743 claims
NovartisEntresto$176$36,81138 claims
GSKTrelegy Ellipta, Breo Ellipta$407$33,92945 claims
Johnson & JohnsonXarelto, Invokana$105$33,67941 claims
AstraZenecaFarxiga$567$33,63930 claims
Astellas Pharma US IncMyrbetriq$154$23,32229 claims
AbbVieLinzess$974$21,10933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →